Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects

Current Medical Research and Opinion

Volumn 28, Issue 7, 2012, Pages 1213-1220

  Shin, Donghoon ^a   Kim, Tae Eun ^a   Yoon, Seo Hyun ^a   Cho, Joo Youn ^a   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a,b  

^a Seoul National University   (South Korea)

^b NONE   (South Korea)

Author keywords

Drug interactions; Healthy subjects; Lobeglitazone; Metformin; Pharmacokinetics

Indexed keywords

LOBEGLITAZONE; METFORMIN;

ABNORMAL FECES; ADULT; AREA UNDER THE CURVE; ARTICLE; COLD SWEAT; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPEPSIA; EYE SWELLING; FATIGUE; FLUSHING; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; KOREA; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; OCULAR PRURITUS; OPEN STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SEDATION; SIDE EFFECT; SOMNOLENCE; SORE THROAT; TANDEM MASS SPECTROMETRY; THORAX PAIN; THROAT TIGHTNESS; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84863619181     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.703131     Document Type: Article

References (22)

1. Setter SM, Iltz JL, Thams J, et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Therapeut 2003;25:2991-3026 (Pubitemid 38096142)
2. Bloomgarden ZT. Diabetes treatment. Diabetes Care 2009;32:e25-30
3. Scheen AJ, Lefebvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998;55:225-36 (Pubitemid 28081625)
4. Bell DS. Type 2 diabetes mellitus: what is the optimal treatment regimen? Am J Med 2004;116:23S-29S (Pubitemid 38333038)
5. Bermudex V, Finol F, Parra N, et al. PPAR-gamma agonists and their role in type 2 diabetes mellitus management. Am J Therapeut 2010;17:274-83
6. Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Exper Opin Investig Drugs 2006;15:243-50 (Pubitemid 43338145)
7. Elte JW, Blickle JF. Thiazolidinediones for the treatment of type 2 diabetes. Eur J Intern Med 2007;18:18-25 (Pubitemid 46072729)
8. Kim BY, Ahn JB, Lee HW, et al. Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione. Eur J Med Chem 2004;39:433-47 (Pubitemid 38526360)
9. Lee HW, Kim BY, Ahn JB, et al. Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur J Med Chem 2005;40: 862-74 (Pubitemid 41376301)
10. Kim JW, Kim J, Yi S, et al. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a PPAR g agonist, in healthy male Korean subjects. Clin Therapeut 2011;33:1819-30
11. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Therapeut 2000;22: 1395-409 (Pubitemid 32056079)
12. Prato SD, Volpe L. Rosiglitazone plus metformin: combination therapy for type 2 diabetes. Expert Opin Pharmacother 2004;5:1411-22 (Pubitemid 38885798)
13. Guideline for Good Clinical Practice Efficacy Guidelines. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Available at: http://www.ich.org/products/ guidelines/efficacy/article/efficacy-guidelines.html [Last accessed 28 December 2011]
14. Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html [Last accessed 28 December 2011]
15. Shin H-S, Seo HB, Shin JS. Quantitative determination of CKD-501 by high turbulence liquid chromatography-tandem mass spectrometry in human plasma and urine. 17th International Mass Spectrometry Conference. Prague, Czech Repulic: IMSC 2006;2006:MoP-105
16. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. 4th edn. Sweden: Swedish Pharmaceutical Press, 2007
17. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72 (Pubitemid 34256388)
18. Zhang L, Reynolds KS, Zhao P, et al. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol 2010;243:134-45
19. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (FDA, CDER). Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070244.pdf [Last accessed 28 December 2011]
20. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12: 235-46 (Pubitemid 11034446)
21. Graham GG, Punt J, Arora M, et al. Clinical Pharmacokinetics. Clinical pharmacokinetics of metformin. 2011;50:81-98
22. GLUCOPHAGE (metformin hydrochloride tablets). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/020357s031,02120 2s016lbl.pdf [Last accessed 28 December 2011]